These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28860722)

  • 1. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.
    Liu FX; Witt EA; Ebbinghaus S; DiBonaventura Beyer G; Shinde R; Basurto E; Joseph RW
    Patient Prefer Adherence; 2017; 11():1389-1399. PubMed ID: 28860722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment.
    Liu FX; Witt EA; Ebbinghaus S; DiBonaventura Beyer G; Basurto E; Joseph RW
    Cancer Nurs; 2019; 42(1):E52-E59. PubMed ID: 29076867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.
    Maculaitis MC; Liu X; Will O; Hanson M; McRoy L; Berk A; Crastnopol M
    Patient Prefer Adherence; 2020; 14():2201-2214. PubMed ID: 33177814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
    Stone RL; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Ritz S; Mulvihill E; Monberg M; Szamreta EA; Amin S; McLaurin K
    Future Oncol; 2022 Feb; 18(4):491-503. PubMed ID: 34875854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects.
    Le H; Ryan K; Wahlstrom SK; Maculaitis MC; Will O; Mulvihill E; LeBlanc TW
    Patient Prefer Adherence; 2021; 15():99-110. PubMed ID: 33519195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists' and Urologists' Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries.
    Panattoni L; Kearney M; Land N; Flottemesch T; Sullivan P; Kirker M; Bharmal M; Hauber B
    Pharmacoeconomics; 2024 Aug; 42(8):895-909. PubMed ID: 38472738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment.
    Yong C; Cambron-Mellott MJ; Seal B; Will O; Maculaitis MC; Clapp K; Mulvihill E; Cotarla I; Mehra R
    Patient Prefer Adherence; 2022; 16():123-135. PubMed ID: 35068928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists.
    Fernández O; Lázaro-Quintela M; Crespo G; Soto de Prado D; Pinto Á; Basterretxea L; Gómez de Liaño A; Etxaniz O; Blasco S; Gabás-Rivera C; Aceituno S; Palomar V; Polanco-Sánchez C
    Front Oncol; 2021; 11():773366. PubMed ID: 35070976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment.
    Beusterien K; Maculaitis MC; Hallissey B; Gaschler MM; Smith ML; Law EH
    Patient Prefer Adherence; 2021; 15():611-623. PubMed ID: 33776424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives.
    Amin S; Tolaney SM; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Mulvihill E; Shinde R; McLaurin K
    Future Oncol; 2022 May; 18(16):1927-1941. PubMed ID: 35249366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study.
    Mansfield C; Botha W; Vondeling GT; Klein K; Wang K; Singh J; Hackshaw MD
    Breast Cancer; 2023 Jan; 30(1):23-35. PubMed ID: 36074320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers.
    MacEwan JP; Doctor J; Mulligan K; May SG; Batt K; Zacker C; Lakdawalla D; Goldman D
    MDM Policy Pract; 2019; 4(1):2381468319855386. PubMed ID: 31259249
    [No Abstract]   [Full Text] [Related]  

  • 13. Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment.
    Janse S; Janssen E; Huwig T; Basu Roy U; Ferris A; Presley CJ; Bridges JFP
    Curr Med Res Opin; 2021 Apr; 37(4):643-653. PubMed ID: 33571024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment.
    González JM; Ogale S; Morlock R; Posner J; Hauber B; Sommer N; Grothey A
    Cancer Manag Res; 2017; 9():149-158. PubMed ID: 28490902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient and Oncologist Preferences for the Treatment of Adults with Advanced Soft Tissue Sarcoma: A Discrete Choice Experiment.
    Ivanova J; Hess LM; Garcia-Horton V; Graham S; Liu X; Zhu Y; Nicol S
    Patient; 2019 Aug; 12(4):393-404. PubMed ID: 30659513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
    Fifer S; Rose J; Hamrosi KK; Swain D
    BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Preferences for Cardiac Procedures of Patients With Chronic Kidney Disease in Acute Coronary Syndrome: Design and Pilot Testing of a Discrete Choice Experiment.
    Wilson T; Javaheri P; Finlay J; Hazlewood G; Wilton SB; Sajobi T; Levin A; Pearson W; Connolly C; James MT
    Can J Kidney Health Dis; 2021; 8():2054358120985375. PubMed ID: 33552527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients.
    Grivas P; Veeranki P; Chiu K; Pawar V; Chang J; Bharmal M
    Future Oncol; 2023 Feb; 19(5):369-383. PubMed ID: 36876486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating Oncologists' Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study.
    Gupta S; Costantino H; Ike C; Gupta S; Bhanegaonkar A; Su C; Thakkar S; Mackie DS; Devgan G; Katzenstein HM; Liu FX
    Oncologist; 2024 Mar; 29(3):244-253. PubMed ID: 37846191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient preferences for treatment of advanced melanoma: impact of comorbidities.
    Weilandt J; Diehl K; Schaarschmidt ML; Kiecker F; Sasama B; Pronk M; Ohletz J; Könnecke A; Müller V; Utikal J; Hillen U; Harth W; Peitsch WK
    J Dtsch Dermatol Ges; 2021 Jan; 19(1):58-70. PubMed ID: 33015933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.